Table 3.

IC₅₀s for recombinant Cdr1p, Cdr2p, and Mdr1p

Substratea	IC50b for:
	Cdr1p	Cdr2p	Mdr1p
Fluconazole	1.0 ± 0.2	1.0 ± 0.2	1.0 ± 0.7
Voriconazole	0.2 ± 0.0	0.3 ± 0.1	0.3 ± 0.2
Posaconazole	0.8 ± 0.3	0.6 ± 0.3	0.7 ± 0.4
Miconazole	0.7 ± 0.3	0.9 ± 0.4	3.1 ± 1.1
Itraconazole	4.4 ± 1.0	2.4 ± 0.6	0.8 ± 0.4
Clotrimazole	5.6 ± 1.3	3.1 ± 1.0	2.0 ± 0.7
β-Estradiol	1.9 ± 0.3	21 ± 7.5	22 ± 10
5-Fluorouracil	9.6 ± 2.3	10 ± 4.9	15 ± 9.0
Progesterone	21 ± 10	32 ± 12	≥50
Cerulenin	33 ± 11	30 ± 9.1	17 ± 6.2
Cycloheximide	7.6 ± 2.8	27 ± 9.6	≥50
Carnosine	12 ± 4.5	≥50	≥50
Am. imidazole	13 ± 3.6	≥50	≥50
Dichlorobenzene	16 ± 3.0	≥50	≥50
Daunorubicin	23 ± 4.9	≥50	≥50
Corticosterone	14 ± 3.8	17 ± 6.8	≥50
Caspofungin	≥50	≥50	≥50
Cyt. arabinose	≥50	≥50	20 ± 4.2
Methotrexate	≥50	≥50	6.7 ± 2.2
Triazole	≥50	≥50	16 ± 3.0
Colchicine	≥50	≥50	11 ± 4.2
Brefeldin A	≥50	≥50	11 ± 3.7

^aAm. imidazole, 1-3-aminopropyl-imidazole; cyt. arabinose, cytosine β-d-arabinofuranoside.

^bExpressed as the ratio of the concentration of each compound to the concentration of fluconazole. Data are means ± SD for 3 experiments.